Switching strategies to improve lipid profile and morphologic changes.

Area of Science:

• HIV/AIDS treatment
• Pharmacology
• Metabolic disorders

Background:

• Protease inhibitor (PI)-based regimens for HIV are linked to metabolic issues and body fat changes.
• Alternative antiretroviral therapies aim to mitigate these adverse effects.
• Lipodystrophy and dyslipidemia are significant concerns in long-term HIV management.

Purpose of the Study:

• To evaluate the metabolic and body fat outcomes of switching from PI-based HAART regimens.
• To compare the efficacy and tolerability of nonnucleoside reverse transcriptase inhibitors (NNRTIs) and abacavir as alternatives.
• To assess the impact on lipid profiles and cardiovascular risk factors.

Main Methods:

• Review of therapeutic options including NNRTIs and abacavir.
• Comparison of metabolic outcomes, lipid profiles (cholesterol, triglycerides, HDL), and body fat changes.
• Analysis of virologic failure rates and tolerability in different patient groups.

Main Results:

• Switching to NNRTIs or abacavir improves metabolic abnormalities, decreasing cholesterol and triglyceride levels.
• Abacavir is better tolerated but may lead to higher virologic failure in specific patient subgroups.
• NNRTIs, particularly nevirapine, improve lipid profiles and the HDL/total cholesterol ratio, reducing cardiovascular risk.
• Substitution of thymidine analogs like stavudine for abacavir or tenofovir improves lipoatrophy and lipid profiles.

Conclusions:

• Therapeutic switching from PIs can significantly improve metabolic health and reduce cardiovascular risk in HIV-infected patients.
• Different antiretroviral drug classes and specific agents offer distinct metabolic and tolerability profiles.
• Optimizing HAART regimens through strategic switching is crucial for improving long-term patient outcomes and quality of life.